Delanzomib
Delanzomib (CEP-18770) is a potent and selective oral proteasome inhibitor, targeting the chymotrypsin-like activity with an IC50 of 3.8 nM while sparing other proteasomal activities. It has demonstrated anti-tumor efficacy in preclinical models of multiple myeloma and solid tumors, supporting its investigation in both in vitro and in vivo cancer research.
Product Specifications
CAS Number
847499-27-8
Product Name Alternative
CEP18770, CEP-18770, CEP 18770, Chymotrypsin-like proteasome, chymotrypsin-like, Delanzomib, anti-cancer, antiangiogenic, Apoptosis, inhibit, Inhibitor, NFkB, NF-kB, Nuclear factor-κB, Nuclear factor-kappaB, NF-κB, NFκB, Proteasome
Field of Research
Cell Biology, Protein Biochemistry, Signal Transduction
Purity
95.52% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.84 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ; DMSO:77 mg/mL (186.31 mM) ; Ethanol:77 mg/mL (186.31 mM)
Smiles
CC (C) C[C@H] (NC (=O) [C@@H] (NC (=O) c1cccc (n1) -c1ccccc1) [C@@H] (C) O) B (O) O
Molecular Formula
C21H28BN3O5
Molecular Weight
413.28
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
